New cancer drug enters first human trials for Tough-to-Treat tumors
NCT ID NCT05174637
Summary
This is a first-in-human study to test the safety and early effectiveness of a new cancer drug called FDA018-ADC in patients with advanced solid tumors that have spread. The main goals are to find the safest dose and see how the body processes the drug. The study includes patients with various advanced cancers, such as triple-negative breast cancer and lung cancer, who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/ METASTATIC SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200000, China
Conditions
Explore the condition pages connected to this study.